trending Market Intelligence /marketintelligence/en/news-insights/trending/-nqXyc9a0Hafj0tgBgTxWg2 content esgSubNav
In This List

Collegium terminates opioid drug license agreement with BioDelivery

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Collegium terminates opioid drug license agreement with BioDelivery

Collegium Pharmaceutical Inc. is returning to BioDelivery Sciences International Inc. the U.S. rights to opioid drug Onsolis.

The companies entered a license and development agreement for the drug in May 2016, and have since been collaborating on the transfer of product manufacturing to a new supplier.

Collegium's decision to terminate the license involves its recent license agreement to commercialize Depomed Inc.'s Nucynta.

The termination will be effective March 8, 2018.